Humira

Recent federal data shows that U.S. prescription drug prices declined 3.1% from a year ago, the steepest drop since 1963. While Donald Trump has taken credit for these drops through “most favored nation” deals, experts suggest other factors are equally significant. These contributors include competition from generic and biosimilar products, as well as policy changes like the Inflation Reduction Act's allowance for Medicare to negotiate drug costs.

U.S. prescription drug prices declined 3.1% from a year ago, marking the steepest drop since 1963. Although President Donald Trump claims credit via 'most favored nation' deals, experts note the price reduction is complex. Contributing factors include Medicare's ability to negotiate costs through policies like the Inflation Reduction Act, and market competition fueled by generic and biosimilar drugs.

Sen. John Cornyn questioned AbbVie CEO Richard Gonzalez during a 2019 congressional hearing about the company's 136 patents on Humira, a drug with the same active molecule used to treat multiple conditions. Gonzalez defended the patents as 'innovations,' extending patent protection beyond the original 2016 expiry. The exchange highlights concerns about pharmaceutical companies leveraging patent portfolios to maintain monopolies.

Generic versions of Ozempic entered the Canadian market after Novo Nordisk allowed its patent to expire, possibly due to failing to pay a $250 filing fee. The move raises questions about whether this was strategic corporate planning or an expensive oversight, as it allows generics to compete while potentially avoiding statutory price caps on patented drugs.